Journal of psychosomatic research · 2025
Clinical and inflammatory markers associated with metabolic dysfunction-associated fatty liver disease in a cohort of individuals with chronic schizophrenia (FACE-SZ).
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tokarski Rudy, Barbosa Susana, Pignon Baptiste, Aouizerate Bruno, Andrieu Christelle, Andre Myrtille, Boukouaci Wahid, Capdevielle Delphine, Chereau Isabelle, Dondé Clément, Kobayashi Julie Clauss, Dorey J M, Dubertret Caroline, Fakra Eric, Fond Guillaume, Goze Tudy, Leignier Sylvain, Llorca Pierre-Michel, Mallet Jasmina, Misdrahi David, Oriol Nicolas, Rey Romain, Roux Paul, Schürhoff Franck, Schorr Benoit, Szöke Andrei, Urbach Mathieu, Very Etienne, Wu Ching-Li, FACE-SZ group, Leboyer Marion, Tamouza Ryad, Godin Ophelia
Аннотация
AIMS: Recent studies on Metabolic dysfunction-associated fatty liver (MAFLD) in schizophrenia show inconsistent findings, often based on small or specific samples. This study aims to assess the prevalence of MAFLD and its sociodemographic, clinical, and treatment-related risk factors in a large cohort of chronic patients with schizophrenia. A secondary goal is to identify an immuno-inflammatory signature associated with MAFLD.
METHODS: 1009 stable outpatients with schizophrenia were included in the cross-sectional analysis. Individuals with liver disease, hepatitis B/C, or current alcohol use disorder were excluded. MAFLD was screened using the Fatty Liver Index (FLI), with FLI > 60 indicating MAFLD. Risk factors were assessed using multivariate logistic regression, and inflammatory markers were analysed with penalized logistic regression.
RESULTS: In a sample of 1009 individuals with schizophrenia, MAFLD prevalence was 36.6 %, higher in men than in women (38.3 % vs 32.0 %, p < 0.0001). Multivariate analysis identified male gender, older age, current smokers, mood stabilizers, antidepressant, clozapine, olanzapine and quetiapine as risk factors for MAFLD. The use of risperidone was associated with a lower risk of MAFLD (0.63 (0.42-0.94). Elevated levels of inflammatory markers such as TNF-α, CRP, and IL-12/IL-23p40 were also linked to a higher likelihood of MAFLD.
CONCLUSION: Although not generalizable to all patients with schizophrenia, this study confirms the high prevalence of MAFLD in individuals with schizophrenia. Psychiatrists should promote healthy lifestyle changes, such as weight control, improved diet, better sleep, and increased physical activity, to improve both physical health and quality of life in these patients.
METHODS: 1009 stable outpatients with schizophrenia were included in the cross-sectional analysis. Individuals with liver disease, hepatitis B/C, or current alcohol use disorder were excluded. MAFLD was screened using the Fatty Liver Index (FLI), with FLI > 60 indicating MAFLD. Risk factors were assessed using multivariate logistic regression, and inflammatory markers were analysed with penalized logistic regression.
RESULTS: In a sample of 1009 individuals with schizophrenia, MAFLD prevalence was 36.6 %, higher in men than in women (38.3 % vs 32.0 %, p < 0.0001). Multivariate analysis identified male gender, older age, current smokers, mood stabilizers, antidepressant, clozapine, olanzapine and quetiapine as risk factors for MAFLD. The use of risperidone was associated with a lower risk of MAFLD (0.63 (0.42-0.94). Elevated levels of inflammatory markers such as TNF-α, CRP, and IL-12/IL-23p40 were also linked to a higher likelihood of MAFLD.
CONCLUSION: Although not generalizable to all patients with schizophrenia, this study confirms the high prevalence of MAFLD in individuals with schizophrenia. Psychiatrists should promote healthy lifestyle changes, such as weight control, improved diet, better sleep, and increased physical activity, to improve both physical health and quality of life in these patients.